Phenibut, the appearance of another potentially dangerous product in the United States

Charles W. O’Connell, Aaron B. Schneir, James Q. Hwang, F. Lee Cantrell

PII: S0002-9343(14)00284-8
DOI: 10.1016/j.amjmed.2014.03.029
Reference: AJM 12468

To appear in: The American Journal of Medicine

Received Date: 6 March 2014
Revised Date: 19 March 2014
Accepted Date: 19 March 2014

Please cite this article as: O’Connell CW, Schneir AB, Hwang JQ, Cantrell FL, Phenibut, the appearance of another potentially dangerous product in the United States, The American Journal of Medicine (2014), doi: 10.1016/j.amjmed.2014.03.029.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Phenibut, the appearance of another potentially dangerous product in the United States
O’Connell, Charles W\textsuperscript{1,2,3}, Schneir Aaron B\textsuperscript{1,3}, Hwang, James Q\textsuperscript{4}, Cantrell, F. Lee\textsuperscript{1,3}

1. Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health System
2. Veterans Affairs San Diego California Health System
3. California Poison Control System, San Diego Division
4. Department of Emergency Medicine, Scripps Memorial Hospital La Jolla

Keywords: phenibut, GABA\textsubscript{B} agonist, β-phenyl-γ-aminobutyric acid, sedative, internet

Running Head: Appearance of Phenibut

All authors had access to the data and an active role in writing and review of the manuscript.

Conflict of interest: none

Funding: none
Since the advent of the internet, many quasi-legal substances with significant toxicity and abuse potential have found their way into the hands of consumers across the United States. In recent years, multiple reports of abuse and withdrawal syndromes related to internet-purchased synthetic cannabinoids and synthetic cathinones known as “bath salts” have become prevalent [1]. We report a patient who reportedly suffered toxicity after using a novel substance named phenibut (β-phenyl-γ-aminobutyric acid). A 25-year-old male with a history of ethanol dependence and depression was found by his roommate to be unconscious and minimally responsive. For the past four days the patient had reportedly been ingesting internet-purchased phenibut at a dose of 1.5 grams twice daily.

Initial vital signs in the ED: blood pressure 110/50 mmHg, pulse 69 beats per minute, temperature 36.2 °F, respirations 14 per minute with a pulse oximetry of 100% on room air. Physical examination revealed significantly depressed level of consciousness. To painful stimuli he would moan, open eyes slightly, and move all extremities equally. His pupils were normal size and reactive. An electrocardiogram was normal, and routine laboratory testing (complete blood count, chemistry, coagulation studies) were normal except for slight hypernatremia (149 mmol/L) and hyperchloremia (108 mmol/L). Serum acetaminophen, salicylate and ethanol were not detected. A
computed tomography brain scan and chest radiograph were unremarkable. Further confirmatory serum testing was not available for phenibut through our hospital’s associated national laboratory clinic.

Over the next seven hours the patient slowly returned to a normal level of consciousness. He denied additional ingestions beyond therapeutic doses of his venlafaxine and mirtazapine. Telephone follow up one week later revealed the patient remained asymptomatic after ceasing further phenibut use.

Although withdrawal from phenibut has been reported in the English literature [2,3], we are not aware of any other published cases involving toxicity from either excessive or “therapeutic” doses. Phenibut was first synthesized in Russia in the 1960s, where it remains in use for anxiolysis as well as pre-operative sedation and alcohol withdrawal. Phenibut is a GABA$_B$ agonist [4] that is structurally similar to the widely prescribed GABA$_B$ agonist baclofen, differing by only a single chlorine molecule. Given its mechanism of action, one would expect a sedative/hypnotic presentation as demonstrated in our patient.

Little is published regarding the pharmacokinetics of phenibut, and it is unclear in our case why toxicity manifested on the fourth day of use. Suggested daily doses range from 500 to 2000 mg; our patient’s consumption exceeded maximal suggested dose by 1000 mg daily. In addition to central sedation caused by phenibut, it is plausible our patient could have had potentiation or interaction with his neuroleptics leading to increased sedation. Potentiation of other medications with concomitant phenibut use has been demonstrated in animal models [5].
In order to determine if our case was the sentinel case reported to poison control centers in California, we searched and subsequently found 3 additional cases of phenibut toxicity (2 with “normal” use and one from withdrawal) had been reported within the previous 6 months. This raises serious concerns because phenibut has pharmacological activity found only in prescription medications in the United States and is easily obtainable. A simple internet search utilizing Google with search phrase “buy phenibut” yielded 20 different retail sites, including vendors Walmart and Ebay. Phenibut-related problems are beginning to increase in the United State and physicians should be aware of its presence and adverse effects.